Tag: Head and neck cancer

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

businessnewstoday- July 11, 2023

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More

Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India

businessnewstoday- May 31, 2023

Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is ... Read More

Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC

businessnewstoday- October 5, 2022

Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More

PDS Biotechnology gets FDA fast track status for PDS0101

pallavi123- June 5, 2022

PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More

ImmVira wraps up first dosing for MVR-T3011 in US and China

pallavi123- June 13, 2021

ImmVira said that it has wrapped up the first dosing of its oncolytic virus product - MVR-T3011 intratumoral injection in phase 2 clinical trials both ... Read More

MiraDx to enroll patients for non-tumor based microRNA clinical trial

pharmanewsdaily- January 10, 2020

MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven ... Read More

FDA lifts clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial

pharmanewsdaily- July 15, 2018

Advaxis revealed that the US Food and Drug Administration (FDA) has removed a previously imposed clinical hold on its Phase 1/2 trial of Axalimogene Filolisbac ... Read More